>Mercado Ásia-Pacífico de Síndrome de Desconforto Respiratório Agudo (ARDS), por causa (Doença de Coronavírus 2019 (COVID-19), Sepse, Inalação de Substâncias Nocivas, Pneumonia Grave e Outros), Tipo (Diagnóstico e Tratamento), Via de Administração (Oral , Parentérica e Outros), Utilizador Final (Hospitais, Clínicas Especializadas, Assistência Médica Domiciliária e Outros), Canal de Distribuição (Concurso Directo, Farmácia Hospitalar, Farmácia de Retalho, Farmácia Online e Outros), País (Japão, China, Coreia do Sul, Índia, Austrália, Singapura, Tailândia, Malásia, Indonésia, Filipinas, Vietname e Resto da Ásia-Pacífico) Tendências e previsões da indústria para 2029.
Análise de mercado e insights : Mercado de Síndrome de Dificuldade Respiratória Aguda (SDRA) da Ásia-Pacífico
Espera-se que o mercado da síndrome de desconforto respiratório agudo (ARDS) da Ásia-Pacífico ganhe crescimento de mercado no período de previsão de 2022 a 2029. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 11,1 % no período de previsão de 2022 a 2029. e deverá atingir os 4.165,51 milhões de dólares até 2029. O aumento da prevalência do COVID-19 atua como motor para o crescimento do mercado da síndrome de desconforto respiratório agudo (ARDS).
A síndrome de desconforto respiratório agudo (SDRA) é uma lesão pulmonar com risco de vida que permite a fuga de líquido para os pulmões. A maioria das pessoas que contrai SDRA já está no hospital por trauma ou doença como a COVID-19. A síndrome ocorre geralmente quando os fluidos se acumulam nos pequenos sacos de ar elásticos chamados alvéolos nos pulmões. Esta acumulação de fluido faz com que menos oxigénio chegue à corrente sanguínea. Isto priva os órgãos de obter oxigénio suficiente para o seu funcionamento normal. As pessoas com outras doenças desenvolvem SDRA dentro de algumas horas ou dias após a lesão ou infeção precipitante. O risco de morte aumenta com a idade e dependendo da gravidade da doença torna-se difícil sobreviver à síndrome. Doença grave ou lesão que causa danos nas membranas dos pulmões leva à SDRA. As causas subjacentes mais comuns para as referidas doenças incluem sépsis , inalação de substâncias nocivas, pneumonia grave, lesões graves na cabeça, no peito ou outras lesões graves, doença por coronavírus 2019 (COVID-19) e outras.
O aumento da prevalência e incidência de lesão pulmonar aguda, ampla gama de fatores de risco para SDRA e aceleração no pool de doentes de COVID-19 com SDRA atuam como impulsionadores para o mercado da síndrome de desconforto respiratório agudo (SDRA). Os outros fatores que deverão impulsionar o crescimento do mercado da síndrome de desconforto respiratório agudo (ARDS) da Ásia-Pacífico incluem a taxa crescente de poluição do ar e doenças relacionadas com o estilo de vida e o aumento das taxas de acidentes e traumas que causam SDRA .
No entanto, fatores como as complicações associadas aos tratamentos, o elevado custo dos dispositivos e tratamentos estão a dificultar o crescimento do mercado da síndrome de desconforto respiratório agudo (SDRA) da Ásia-Pacífico. Por outro lado, a crescente população geriátrica, o aumento dos gastos em saúde e as iniciativas estratégicas dos participantes do mercado funcionam como uma oportunidade para o crescimento do mercado da síndrome de desconforto respiratório agudo (SDRA) da Ásia-Pacífico. Os rigorosos regulamentos para aprovação e os múltiplos desafios enfrentados pelos enfermeiros de UCI são o principal desafio de mercado enfrentado no mercado da síndrome de desconforto respiratório agudo (ARDS) da Ásia-Pacífico.
O relatório de mercado da síndrome de desconforto respiratório agudo (ARDS) fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, mudanças nas regulamentos de mercado, aprovações de produtos, decisões de estratégia, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário de mercado da síndrome de desconforto respiratório agudo (SDRA), contacte a Data Bridge Market Research para obter um resumo do analista, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.
Âmbito e dimensão do mercado da Síndrome de Dificuldade Respiratória Aguda (ARDS)
O mercado da síndrome de desconforto respiratório agudo (ARDS) está segmentado com base na causa, tipo, via de administração, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base na causa, o mercado da síndrome de angústia respiratória aguda (ARDS) da Ásia-Pacífico está segmentado em doença coronavírus 2019 (COVID-19), sépsis, inalação de substâncias nocivas, pneumonia grave e outros. Em 2022, espera-se que o segmento da doença coronavírus 2019 (COVID-19) domine o mercado, uma vez que o número de casos na região foi elevado desde a sua origem na China.
- Com base no tipo, o mercado da síndrome de angústia respiratória aguda (ARDS) da Ásia-Pacífico está segmentado em diagnóstico e tratamento. Em 2022, prevê-se que o segmento de diagnóstico domine o mercado devido ao aumento do número de instalações hospitalares e de diagnóstico para fornecer tratamentos atempados.
- Com base na via de administração, o mercado da síndrome de desconforto respiratório agudo (ARDS) da Ásia-Pacífico está segmentado em oral, parentérica e outras. O segmento parentérico é ainda segmentado em intramuscular e intravenoso. Em 2022, prevê-se que o segmento parentérico domine o mercado devido ao elevado número de participantes de mercado que operam no segmento.
- Com base no utilizador final, o mercado da síndrome de desconforto respiratório agudo (ARDS) da Ásia-Pacífico está segmentado em hospitais, clínicas especializadas, cuidados de saúde domiciliários e outros. Em 2022, prevê-se que o segmento dos hospitais domine o mercado, uma vez que a maioria das pessoas prefere os hospitais para o diagnóstico seguido de tratamentos.
- Com base no canal de distribuição, o mercado da síndrome de angústia respiratória aguda (ARDS) da Ásia-Pacífico está segmentado em concurso direto, farmácia hospitalar, farmácia de retalho, farmácia online e outros. Em 2022, prevê-se que o segmento do concurso direto domine o mercado devido ao preço justo dos produtos vendidos pelos fabricantes.
Análise ao nível do país do mercado de Síndrome de Dificuldade Respiratória Aguda (SDRA)
O mercado da síndrome de desconforto respiratório agudo (ARDS) é analisado e as informações sobre o tamanho do mercado são fornecidas pelo país, cinco segmentos notáveis, tais como causa, tipo, via de administração, utilizador final e canal de distribuição como mencionado acima.
Os países abrangidos no relatório de mercado da síndrome de desconforto respiratório agudo (SDRA) são o Japão, China, Coreia do Sul, Índia, Austrália, Singapura, Tailândia, Malásia, Indonésia, Filipinas, Vietname e Resto da Ásia-Pacífico.
Espera-se que o segmento parentérico no Japão cresça com a maior taxa de crescimento no período de previsão de 2022 a 2029 devido ao crescente avanço tecnológico no país. O segmento parentérico na China está em segundo lugar dominando o mercado devido ao aumento de casos de doenças respiratórias crónicas e à elevada adoção de diagnósticos adequados. A Coreia do Sul é o terceiro líder no crescimento do mercado Ásia-Pacífico e o segmento parentérico está a dominar neste país devido ao número crescente de centros de biotecnologia e atividades de investigação.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado nacional que impactam as tendências atuais e futuras do mercado. Dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, a presença e disponibilidade de marcas da Ásia-Pacífico e os desafios enfrentados devido à concorrência grande ou escassa de marcas locais e nacionais, o impacto dos canais de vendas são considerados, ao mesmo tempo que fornece uma análise de previsão dos dados do país.
O crescimento das atividades estratégicas dos principais players do mercado para aumentar a consciencialização sobre o tratamento da síndrome de desconforto respiratório agudo (ARDS) está a impulsionar o crescimento do mercado da síndrome de desconforto respiratório agudo (ARDS).
O mercado da síndrome de desconforto respiratório agudo (SDRA) também fornece análises de mercado detalhadas para o crescimento de cada país num mercado específico. Além disso, fornece informações detalhadas sobre a estratégia dos intervenientes no mercado e a sua presença geográfica. Os dados estão disponíveis para o período histórico de 2011 a 2020.
Análise do panorama competitivo e da quota de mercado da Síndrome de Dificuldade Respiratória Aguda (SDRA)
O panorama competitivo do mercado da Síndrome de desconforto respiratório agudo (SDRA) fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura e amplitude do produto, domínio de aplicação, curva de segurança da tecnologia. Os dados acima fornecidos estão apenas relacionados com o foco da empresa relacionado com o mercado da síndrome de desconforto respiratório agudo (SDRA).
Algumas das principais empresas que lidam com a síndrome de desconforto respiratório agudo (SDRA) são a Fisher & Paykel Healthcare Limited., a LivaNova PLC, a Gilead Sciences, Inc., a Fresenius SE & Co. Smiths Medical (parte da ICU Medical, Inc.), ResMed, Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, nice Neotech Medical Systems Unip. Ltd., Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, NIPRO, Terumo Medical Corporation, Getinge AB., EUROSETS e entre outros players nacionais. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.
Muitos contratos e acordos são também iniciados pelas empresas de todo o mundo que também estão a acelerar o mercado da síndrome de desconforto respiratório agudo (SDRA).
Por exemplo,
- Em maio de 2021, a Medtronic anunciou o lançamento do sistema de monitorização das vias aéreas SonarMed. O sistema utiliza tecnologia acústica para verificar a obstrução do tubo endotraqueal. Isto ajudou a empresa a aumentar o seu portfólio de produtos.
- Em julho de 2020, a F. Hoffman-La Roche Ltd anunciou o lançamento do teste rápido de anticorpos SARS-CoV-2. O teste foi lançado em parceria com a SD Biosenseor, Inc. Isto ajudou a empresa a aumentar o seu portefólio de produtos.
A colaboração, o lançamento de produtos, a expansão de negócios, a atribuição de prémios e reconhecimento, as joint ventures e outras estratégias do player de mercado estão a melhorar a pegada da empresa no mercado da síndrome de desconforto respiratório agudo, o que também oferece o benefício para o crescimento do lucro da organização.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 CAUSE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
5 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: REGULATIONS
5.1 REGULATION IN U.S.:
5.2 REGULATION FOR VENTILATORS AND RESPIRATORY DEVICES AS PER FDA
5.3 REGULATION FOR THE USE OF VENTILATOR AND ANESTHESIA GAS MACHINE BREATHING CIRCUIT DEVICES
5.4 LABELING OF MODIFIED DEVICES
5.5 REGULATION IN EUROPE:
5.6 REGULATION IN INDIA:
5.7 REGULATION IN JAPAN:
6 REGIONAL SUMMARY
6.1 NORTH AMERICA REGION
6.2 EUROPE REGION
6.3 ASIA-PACIFIC
6.4 SOUTH AMERICA
6.5 MIDDLE EAST AND AFRICA
7 PIPELINE ANALYSIS
8 INSURANCE REIMBURSEMENT
8.1 CENTER FOR MEDICARE SERVICES (CMS)–ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION)
8.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION
8.3 ABBOTT CODING GUIDE FOR ECMO
8.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS)
8.5 CERN HEALTH INSURANCE SCHEME
8.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) – (MEDICARE & MEDICAID)
8.7 AMERICAN HOSPITAL ASSOCIATION
8.8 CONCLUSION
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY
9.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS
9.1.3 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS
9.1.4 RISING RATE OF AIR POLLUTION AND LIFESTYLE-RELATED DISEASES
9.1.5 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS
9.2 RESTRAINTS
9.2.1 COMPLICATIONS ASSOCIATED WITH TREATMENTS
9.2.2 HIGH COST OF DEVICE AND TREATMENTS
9.2.3 LACK OF SKILLED WORKFORCE
9.3 OPPORTUNITIES
9.3.1 GROWING GERIATRIC POPULATION
9.3.2 RISING HEALTHCARE EXPENDITURE
9.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS
9.3.4 IMPROVING AWARENESS REGARDING ARD SYNDROME
9.4 CHALLENGES
9.4.1 STRINGENT RULES & REGULATIONS
9.4.2 MULTIPLE CHALLENGES FACED BY ICU NURSES
10 IMPACT OF COVID-19 PANDEMIC ON THE ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET
10.1 PRICE IMPACT
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS
10.5 CONCLUSION
11 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE
11.1 OVERVIEW
11.2 DIAGNOSIS
11.2.1 IMAGING TESTS
11.2.1.1 CHEST X-RAY
11.2.1.2 CT SCAN
11.2.1.3 ULTRASOUND
11.2.1.4 OTHERS
11.2.2 BLOOD TEST
11.2.3 RESPIRATORY RATE
11.2.4 SPO2 TEST
11.2.5 OTHERS
11.3 TREATMENT
11.3.1 MECHANICAL VENTILATION
11.3.1.1 HIGH-FLOW NASAL O2
11.3.1.2 BI-LEVEL POSITIVE AIRWAY PRESSURE
11.3.1.3 CONTINOUS POSITIVE AIRWAY PRESSURE
11.3.1.4 PRONE POSITIVE VENTILATION
11.3.1.5 OTHERS
11.3.2 CORTICOSTEROIDS
11.3.2.1 METHYLPREDNISOLONE
11.3.2.2 DEXAMETHASONE
11.3.2.3 OTHERS
11.3.3 ANTIVIRAL MEDICATION
11.3.3.1 REMDESIVIR
11.3.3.2 COMBINATION DRUGS
11.3.3.3 OTHERS
11.3.4 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
11.3.5 TOCILIZUMAB
11.3.6 OTHERS
12 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 PARENTERAL
12.2.1 INTRAVENOUS
12.2.2 INTRAMUSCULAR
12.3 ORAL
12.4 OTHERS
13 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE
13.1 OVERVIEW
13.2 CORONAVIRUS DISEASE 2019 (COVID-19)
13.3 SEPSIS
13.4 INHALATION OF HARMFUL SUBSTANCES
13.5 SEVERE PNEUMONIA
13.6 OTHERS
14 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS
15 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 HOSPITAL PHARMACY
15.4 RETAIL PHARMACY
15.5 ONLINE PHARMACY
16 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION
16.1 ASIA-PACIFIC
16.1.1 JAPAN
16.1.2 CHINA
16.1.3 SOUTH KOREA
16.1.4 INDIA
16.1.5 AUSTRALIA
16.1.6 SINGAPORE
16.1.7 THAILAND
16.1.8 MALAYSIA
16.1.9 INDONESIA
16.1.10 PHILIPPINES
16.1.11 VIETNAM
16.1.12 REST OF ASIA-PACIFIC
17 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 GILEAD SCIENCES INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUS ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 TERUMO CORPORATION
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUS ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 GETINGE AB
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUS ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 LIVANOVA PLC
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 MEDTRONIC
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 ALUNG TECHNOLOGIES, INC
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 ARMSTRONG MEDICAL
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 BESMED HEALTH BUSINESS CORP.
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 DRÄGERWERK AG & CO. KGAA
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENTS
19.1 EUROSETS
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 F. HOFFMANN-LA ROCHE LTD
19.11.1 COMPANY SNAPSHOT
19.11.2 RECENT ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 FISHER & PAYKEL HEALTHCARE LIMITED
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 FRESENIUS SE & CO. KGAA
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUS ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 HAMILTON MEDICAL
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD.
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENT
19.16 NIPRO
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUS ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 PFIZER INC.
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUS ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENT
19.18 RESMED
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 SMITHS MEDICAL
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUS ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tabela
TABLE 1 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: PIPELINE ANALYSIS
TABLE 2 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 3 ASIA PACIFIC DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC ORAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC CORONAVIRUS DISEASE 2019 (COVID-19) IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC SEPSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC INHALATION OF HARMFUL SUBSTANCES IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC SEVERE PNEUMONIA IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC HOSPITALS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC SPECIALTY CLINICS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC HOME HEALTHCARE IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC DIRECT TENDER IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC HOSPITAL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC RETAIL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC ONLINE PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 33 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 34 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 35 ASIA-PACIFIC DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 ASIA-PACIFIC IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 ASIA-PACIFIC TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 ASIA-PACIFIC ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 ASIA-PACIFIC CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 45 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 46 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 JAPAN DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 JAPAN IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 JAPAN TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 JAPAN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 JAPAN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 JAPAN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 54 JAPAN PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 55 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 56 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 57 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 58 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 CHINA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 CHINA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 CHINA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 CHINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 CHINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 CHINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 66 CHINA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 67 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 68 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 69 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 70 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 71 SOUTH KOREA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 SOUTH KOREA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 SOUTH KOREA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 74 SOUTH KOREA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 SOUTH KOREA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 SOUTH KOREA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 78 SOUTH KOREA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 79 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 80 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 81 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 82 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 INDIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 84 INDIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 85 INDIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 INDIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 INDIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 88 INDIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 90 INDIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 91 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 92 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 93 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 94 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 95 AUSTRALIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 AUSTRALIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 AUSTRALIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 AUSTRALIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 AUSTRALIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 AUSTRALIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 102 AUSTRALIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 103 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 104 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 105 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 106 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 SINGAPORE DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 SINGAPORE IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 SINGAPORE TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 SINGAPORE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 SINGAPORE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 112 SINGAPORE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 113 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 114 SINGAPORE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 115 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 116 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 117 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 118 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 THAILAND DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 120 THAILAND IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 THAILAND TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 122 THAILAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 123 THAILAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 THAILAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 126 THAILAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 127 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 128 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 129 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 130 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 MALAYSIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 132 MALAYSIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 MALAYSIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 MALAYSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 135 MALAYSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 136 MALAYSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 137 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 138 MALAYSIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 139 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 140 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 141 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 142 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 143 INDONESIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 INDONESIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 INDONESIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 INDONESIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 147 INDONESIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 148 INDONESIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 149 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 150 INDONESIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 151 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 152 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 153 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 154 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 155 PHILIPPINES DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 156 PHILIPPINES IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 157 PHILIPPINES TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 158 PHILIPPINES ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 159 PHILIPPINES CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 PHILIPPINES MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 161 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 162 PHILIPPINES PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 163 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 164 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 165 VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 166 VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 167 VIETNAM DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 168 VIETNAM IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 169 VIETNAM TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 170 VIETNAM ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 171 VIETNAM CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 VIETNAM MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 173 VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 174 VIETNAM PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 175 VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 176 VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 177 REST OF ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
Lista de Figura
FIGURE 1 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION
FIGURE 11 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS IS EXPECTED TO DRIVE THE ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 CORONAVIRUS DISEASE 2019 (COVID-19) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET
FIGURE 15 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2021
FIGURE 16 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 17 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 18 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 20 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 21 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 22 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 23 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2021
FIGURE 24 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2020-2029 (USD MILLION)
FIGURE 25 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, CAGR (2022-2029)
FIGURE 26 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2021
FIGURE 28 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 29 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, CAGR (2022-2029)
FIGURE 30 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DISTRIBUTION CHANNEL, 2021
FIGURE 32 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 33 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 34 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SNAPSHOT (2021)
FIGURE 36 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2021)
FIGURE 37 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 38 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 39 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE (2022-2029)
FIGURE 40 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY SHARE 2021 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
